Exforge Money-back Guarantee Leaves DDMAC Complaining
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis sales aid touting money-back guarantee on its blood pressure product implies the drug is more effective than competitors with no head-to-head evidence, FDA maintains.
You may also be interested in...
Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year
CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.
Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year
CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.
Novartis Makes Splash With Hypertension Disease Awareness Program
D.C. press conference to announce “money back guarantee” hypertension treatment program includes HHS Secretary Thompson. Novartis will launch hypertension disease awareness ads in May.